Caplin Point Lab (CAPLIPOINT)
STALWARTFairStock Score: 71/100 — STEADY
Score breakdown: P/E: 1/3 · ROCE: 2/2 · Growth: 2/2 · Dividend: 0/1
Key Financials
| Current Price | ₹1,768.05 |
| Market Cap | ₹12,922.75 Cr |
| P/E Ratio | 21.06 |
| ROCE | 25.85% |
| ROE | 23.3% |
| Dividend Yield | 0.35% |
| Profit Growth | 19.09% |
| Debt/Equity | 0 |
| Sales Growth | 10.66% |
| Free Cash Flow | ₹9,900 Cr |
| Promoter Holding | 70.57% |
| 52-Week Range | ₹1,500.3 — ₹2,424 |
| Sector | Pharmaceuticals & Biotechnology |
| Book Value | ₹346.52 |
Caplin Point Lab trades with a P/E ratio of 21.06, ROCE of 25.85%, ROE of 23.3%, profit growth of 19.09%, debt-to-equity of 0. The FairStock Score of 71/100 reflects strong fundamentals across multiple dimensions.
Data from BSE/NSE filings. AI analysis is for educational purposes only — not investment advice. Scoring methodology · Disclaimer